CN101495485B - 具有抗肿瘤活性的喜树碱衍生物 - Google Patents

具有抗肿瘤活性的喜树碱衍生物 Download PDF

Info

Publication number
CN101495485B
CN101495485B CN2007800281978A CN200780028197A CN101495485B CN 101495485 B CN101495485 B CN 101495485B CN 2007800281978 A CN2007800281978 A CN 2007800281978A CN 200780028197 A CN200780028197 A CN 200780028197A CN 101495485 B CN101495485 B CN 101495485B
Authority
CN
China
Prior art keywords
compound
group
nmr
cdcl
nsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800281978A
Other languages
English (en)
Chinese (zh)
Other versions
CN101495485A (zh
Inventor
G·丰塔纳
E·邦巴尔代利
C·曼佐蒂
A·巴塔哥利亚
C·萨莫里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indena SpA
Original Assignee
Indena SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena SpA filed Critical Indena SpA
Publication of CN101495485A publication Critical patent/CN101495485A/zh
Application granted granted Critical
Publication of CN101495485B publication Critical patent/CN101495485B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
CN2007800281978A 2006-07-26 2007-07-16 具有抗肿瘤活性的喜树碱衍生物 Expired - Fee Related CN101495485B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001474A ITMI20061474A1 (it) 2006-07-26 2006-07-26 Derivati della camptotecina ad attivita antitumorale
ITMI2006A001474 2006-07-26
PCT/EP2007/006294 WO2008012003A1 (en) 2006-07-26 2007-07-16 Camptothecin derivatives with antitumor activity

Publications (2)

Publication Number Publication Date
CN101495485A CN101495485A (zh) 2009-07-29
CN101495485B true CN101495485B (zh) 2012-04-11

Family

ID=38668855

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800281978A Expired - Fee Related CN101495485B (zh) 2006-07-26 2007-07-16 具有抗肿瘤活性的喜树碱衍生物

Country Status (19)

Country Link
US (1) US8193210B2 (enExample)
EP (1) EP2044080B1 (enExample)
JP (1) JP5313895B2 (enExample)
KR (1) KR101496374B1 (enExample)
CN (1) CN101495485B (enExample)
AU (1) AU2007278509B2 (enExample)
BR (1) BRPI0714672B8 (enExample)
CA (1) CA2658902C (enExample)
DK (1) DK2044080T3 (enExample)
ES (1) ES2628022T3 (enExample)
IL (1) IL196652A0 (enExample)
IT (1) ITMI20061474A1 (enExample)
MX (1) MX2009000828A (enExample)
NO (1) NO342506B1 (enExample)
PL (1) PL2044080T3 (enExample)
PT (1) PT2044080T (enExample)
RU (1) RU2450007C2 (enExample)
SI (1) SI2044080T1 (enExample)
WO (1) WO2008012003A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9379559B2 (en) 2012-02-03 2016-06-28 International Business Machines Corporation System and method of charging a vehicle using a dynamic power grid, and system and method of managing power consumption in the vehicle
PL235836B1 (pl) 2012-10-25 2020-11-02 Inst Chemii Organicznej Polskiej Akademii Nauk Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie
CN108690036B (zh) * 2018-05-22 2021-05-25 北京海步医药科技股份有限公司 一种10-二氟甲基喜树碱类化合物及其制备方法和应用
LU102067B1 (en) 2020-09-17 2022-03-18 Narodowy Inst Lekow 7-Ethyl-10-hydroxycamptothecin derivatives for use in the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1282673B1 (it) * 1996-02-23 1998-03-31 Ist Naz Stud Cura Dei Tumori Derivati della camptotecina e loro uso come agenti antitumorali

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972955A (en) * 1995-06-06 1999-10-26 Dr. Reddy's Research Foundation Water soluble C-ring analogues of 20(S)-camptothecin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Duvvuri Subrahmanyam, et al..Novel C-Ring Analogues of 20(S)-camptothecin. Part 3: Synthesis and Their In Vitro Cytotoxicity of A-, B- and C-ring Analogues.《Bioorganic & Medicinal Chemistry Letters》.Elsevier Science Ltd.,2000,第10卷(第4期),369-371. *
Thierry Brunin, et al..Towards new camptothecins. Part 3: Synthesis of 5-methoxycarbonyl camptothecin.《Tetrahedron》.Elsevier Ltd.,2006,第62卷(第17期),3959–3968. *

Also Published As

Publication number Publication date
BRPI0714672B1 (pt) 2020-10-20
BRPI0714672B8 (pt) 2021-05-25
CA2658902C (en) 2014-09-23
CA2658902A1 (en) 2008-01-31
NO20090252L (no) 2009-01-16
CN101495485A (zh) 2009-07-29
KR20090032100A (ko) 2009-03-31
WO2008012003A1 (en) 2008-01-31
US8193210B2 (en) 2012-06-05
NO342506B1 (no) 2018-06-04
RU2450007C2 (ru) 2012-05-10
IL196652A0 (en) 2009-11-18
MX2009000828A (es) 2009-02-03
BRPI0714672A2 (pt) 2013-03-26
AU2007278509A1 (en) 2008-01-31
PL2044080T3 (pl) 2017-10-31
PT2044080T (pt) 2017-06-15
US20100010032A1 (en) 2010-01-14
EP2044080A1 (en) 2009-04-08
HK1135692A1 (en) 2010-06-11
JP2010500971A (ja) 2010-01-14
SI2044080T1 (sl) 2017-07-31
EP2044080B1 (en) 2017-05-10
AU2007278509B2 (en) 2012-10-04
JP5313895B2 (ja) 2013-10-09
RU2009102241A (ru) 2010-07-27
ITMI20061474A1 (it) 2008-01-27
DK2044080T3 (en) 2017-07-17
ES2628022T3 (es) 2017-08-01
KR101496374B1 (ko) 2015-03-04

Similar Documents

Publication Publication Date Title
RU2450008C2 (ru) Производные камптотецина с противоопухолевой активностью
CN101495485B (zh) 具有抗肿瘤活性的喜树碱衍生物
AU2024270034A1 (en) Deuterated camptothecin compound, and preparation therefor and use thereof
JP5198447B2 (ja) 抗腫瘍活性を有するカンプトテシン誘導体
HK1135692B (en) Camptothecin derivatives with antitumor activity
HK1135691B (en) Camptothecin derivatives with antitumor activity
HK1135693B (en) Camptothecin derivatives with antitumor activity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1135692

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1135692

Country of ref document: HK

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120411

CF01 Termination of patent right due to non-payment of annual fee